Voyager Therapeutics Stock Jumps 16% On Collaboration Deal With Neurocrine Biosciences

Shares of Voyager Therapeutics, Inc. (VYGR) is gaining over 16% on Monday morning after Neurocrine Biosciences and Voyager Therapeutics announced a collaboration deal for development and commercialization of Voyager's GBA1 program.

VYGR is currently trading at $8.08, up $1.12 or 16.14%, on the Nasdaq. The stock opened its trading at $8.63 after closing Friday's trading at $6.96. The stock has traded between $2.60 and $10.60 in the past 52-week period.

Voyager Therapeutics announced a deal with Neurocrine Biosciences Inc. (NBIX) to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson's disease.

The collaboration includes Voyager's preclinical, intravenously administered GBA1 gene therapy program for Parkinson's disease and other GBA1-mediated diseases, which combines a GBA1 gene replacement payload with novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform.

In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each also leveraging Voyager's novel TRACER capsids. The collaboration builds upon the long-standing strategic partnership between Neurocrine Biosciences and Voyager and continues to combine Voyager's expertise in novel capsid discovery, payload design, and neuropharmacology with Neurocrine Biosciences' expertise in neuroscience and the clinical and commercial development of therapies for patients suffering from serious neurological diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT